Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents)
  4. Volume 25, Issue 8
  5. Article
Volume 25, Issue 8
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Background

As the number of new cancer cases increases every year, there is a necessity to develop new drugs for the treatment of different types of cancers. Plants' resources are considered to be huge reservoirs for therapeutic agents in nature. Among all the medicinal plants, is one of the most widely used medicinal plants in India, China, and Southeast Asian countries. Combinatorial drug treatment, on the other hand, is favored over single drug treatment in order to target multiple biomolecular moieties that help in the growth and development of cancer. Therefore, combinatorial drug treatment using a co-crystal of multiple drugs gives researchers an idea of the development of a new type of drug for targeting multiple targets. In this study, a new co-crystal of chrysin and oroxylin A was isolated from the leaves of and its anticancer properties were studied in cervical cancer cells HeLa.

Aim

This study was conducted with the aim of identifying new anticancer compounds from the leaves of and studying the anticancer properties of the isolated compound.

Objective

In this study, we elucidated the structure of a new co-crystal compound, which was isolated from the leaf extract of The apoptosis induction mechanism of the newly discovered co-crystal in HeLa cells was also studied.

Methods

A crystal compound from the chloroform extract of leaves of was isolated by solvent fractionation and chromatographic methods involving HPLC. The molecular structure of the isolated crystal was elucidated by Single Crystal-XRD, FT-IR analysis, and further determined by LC-MS. The antiproliferative activity was carried out using an MTT assay and fluorescence microscopy, and the mechanism of apoptosis was determined using Western blotting techniques.

Results

The novel co-crystal consists of two active pharmaceutical ingredients (APIs) in a 1:1 ratio, ., oroxylin A and chrysin. The isolated new co-crystal induced death in HeLa cells with a very low IC value of 8.49 µM. It induced caspase-dependent apoptosis in HeLa cells by activation of Caspase-3 through inhibition of ERKs and activation of p38 of MAPK cell signalling pathway.

Conclusion

This study presents the first report on the discovery of a naturally occurring co-crystal of chrysin and oroxylin A and the involvement of ERKs and p38 of MAPK pathways in the induction of apoptosis in HeLa cells by the co-crystal. Our study sheds light on the development of a co-crystal of chrysin and oroxylin A in a specific ratio of 1:1 for combination therapy of the two APIs. The purified co-crystal was found to be more efficient compared to the compounds present individually. Further analysis of the physiochemical properties and molecular mechanisms of the isolated co-crystal in different cancer cells is warranted for its application in therapeutics.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206364530241128044041
2024-12-13
2025-06-20

  • From This Site

    /content/journals/acamc/10.2174/0118715206364530241128044041
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FerlayJ. Global Cancer Observatory: Cancer Today.Lyon, FranceInternational Agency for Research on Cancer202010.1002/ijc.33588
     [Google Scholar]
  2. GuidaF. KidmanR. FerlayJ. SchüzJ. SoerjomataramI. KithakaB. GinsburgO. Mailhot VegaR.B. GalukandeM. ParhamG. VaccarellaS. CanfellK. IlbawiA.M. AndersonB.O. BrayF. dos-Santos-SilvaI. McCormackV. Global and regional estimates of orphans attributed to maternal cancer mortality in 2020.Nat. Med.202228122563257210.1038/s41591‑022‑02109‑2 36404355
     [Google Scholar]
  3. RamírezM.H. LópezK.G. CarrancáA. Polyphenols as antitumor agents targeting key players in cancer-driving signaling pathways.Front. Pharmacol.20211271030410.3389/fphar.2021.710304 34744708
     [Google Scholar]
  4. GolmohammadiM. ZamanianM.Y. JalalS.M. NoraldeenS.A.M. Ramírez-CoronelA.A. OudahaK.H. ObaidR.F. AlmullaA.F. BazmandeganG. KamiabZ. A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action.Food Sci. Nutr.202311127458746810.1002/fsn3.3699 38107139
     [Google Scholar]
  5. Guamán-OrtizL. OrellanaM. RatovitskiE. Natural compounds as modulators of non-apoptotic cell death in cancer cells.Curr. Genomics201718213215510.2174/1389202917666160803150639 28367073
     [Google Scholar]
  6. ZamanianM.Y. GolmohammadiM. YumashevA. HjaziA. ToamaM.A. AbdRabou, M.A.; Gehlot, A.; Alwaily, E.R.; Shirsalimi, N.; Yadav, P.K.; Moriasi, G. Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways.Cell Biochem. Funct.2024424e407110.1002/cbf.4071 38863255
     [Google Scholar]
  7. KhanT. Anticancer plants: A review of the active phytochemicals, applications in animal models, and regulatory aspects.Biomolecules20191014710.3390/biom10010047
     [Google Scholar]
  8. Van HasseltJ.C. IyengarR.J.A. Systems pharmacology: Defining the interactions of drug combinations.Annu. Rev. Pharmacol. Toxicol.201959214010.1146/annurev‑pharmtox‑010818‑021511
     [Google Scholar]
  9. VakilV. TrappeW.J.P. Drug combinations: Mathematical modeling and networking methods.Pharmaceutics201911520810.3390/pharmaceutics11050208
     [Google Scholar]
  10. FrantzS.J.N. The trouble with making combination drugs.Nat. Rev. Drug Discov.2006588188210.1038/nrd2188
     [Google Scholar]
  11. WangX. Drug-drug cocrystals: Opportunities and challenges.Asian J. Pharm. Sci.202116330731710.1016/j.ajps.2020.06.004
     [Google Scholar]
  12. Kumar BandaruR. RoutS.R. KenguvaG. GorainB. AlhakamyN.A. KesharwaniP. DandelaR. Recent advances in pharmaceutical cocrystals: From bench to market.Front. Pharmacol.20211278058210.3389/fphar.2021.780582 34858194
     [Google Scholar]
  13. KaraD.D. RathnanandM. Cocrystals and drug–drug cocrystals of anticancer drugs: A perception towards screening techniques, preparation, and enhancement of drug properties.Crystals20221210133710.3390/cryst12101337
     [Google Scholar]
  14. SinghV. ChaudharyA.J.I.J. A review on the taxonomy, ethnobotany, chemistry and pharmacology of Oroxylum indicum Vent.Indian J. Pharm. Sci.201173548349010.4103/0250‑474X.98981
     [Google Scholar]
  15. WuB.L. WuZ-W. YangF. ShenX-F. WangL. ChenB. LiF. WangM-K. Flavonoids from the seeds of Oroxylum indicum and their anti-inflammatory and cytotoxic activities.Phytochem. Lett.201932666910.1016/j.phytol.2019.05.003
     [Google Scholar]
  16. YanR. CaoY. ChenC. DaiH. YuS. WeiJ. LiH. YangB. Antioxidant flavonoids from the seed of Oroxylum indicum.Fitoterapia201182684184810.1016/j.fitote.2011.04.006 21596112
     [Google Scholar]
  17. ChenJ. ChenJ. LuJ. Systematic elucidation of the mechanism of Oroxylum indicum via network pharmacology.Evid. Based Complement. Alternat. Med.202020201535421510.1155/2020/5354215 32733583
     [Google Scholar]
  18. DindaB. SilSarma, I.; Dinda, M.; Rudrapaul, P. Oroxylum indicum (L.) Kurz, an important Asian traditional medicine: From traditional uses to scientific data for its commercial exploitation.J. Ethnopharmacol.201516125527810.1016/j.jep.2014.12.027 25543018
     [Google Scholar]
  19. SinghA.R. SinghS.A. SinghT.D. SinghN.T. MachathoibiT.C. SinghO.M. SinghL.S. Bioassay-guided isolation of 2-[p-(2-Carboxyhydrazino)phenoxy]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol from Oroxylum indicum and the investigation of its molecular mechanism action of apoptosis induction.Pharmaceuticals202215555910.3390/ph15050559 35631385
     [Google Scholar]
  20. SheldrickG.M. A short history of SHELX.Acta Crystallogr. A200864111212210.1107/S0108767307043930 18156677
     [Google Scholar]
  21. RenkoğluP. ÇelebierM. YeginA.B. HPLC determination of olanzapine and carbamazepine in their nicotinamide cocrystals and investigation of the dissolution profiles of cocrystal tablet formulations.Pharm. Dev. Technol.201520338038410.3109/10837450.2014.882937 24521464
     [Google Scholar]
  22. RainaR. AfrozeN. Kedhari SundaramM. HaqueS. BajboujK. HamadM. HussainA. Chrysin inhibits propagation of HeLa cells by attenuating cell survival and inducing apoptotic pathways.Eur. Rev. Med. Pharmacol. Sci.20212552206222010.26355/eurrev_202103_25253 33755959
     [Google Scholar]
  23. RainaR. HussainA. AlmutaryA.G. HaqueS. RazaT. D’SouzaA.C. SubramaniS. SajeevanA. Co-administration of chrysin and luteolin with cisplatin and topotecan exhibits a variable therapeutic value in human cancer cells, HeLa.ACS Omega2023844412044121310.1021/acsomega.3c04443 37970041
     [Google Scholar]
  24. ZhangT. ChenX. QuL. WuJ. CuiR. ZhaoY. Chrysin and its phosphate ester inhibit cell proliferation and induce apoptosis in Hela cells.Bioorg. Med. Chem.200412236097610510.1016/j.bmc.2004.09.013 15519155
     [Google Scholar]
  25. KhooB.Y. ChuaS.L. BalaramP. Apoptotic effects of chrysin in human cancer cell lines.Int. J. Mol. Sci.20101152188219910.3390/ijms11052188 20559509
     [Google Scholar]
  26. PawarJ.S. MustafaS. GhoshI. Chrysin and Capsaicin induces premature senescence and apoptosis via mitochondrial dysfunction and p53 elevation in Cervical cancer cells.Saudi J. Biol. Sci.20222953838384710.1016/j.sjbs.2022.03.011 35844432
     [Google Scholar]
  27. LiH.N. NieF.F. LiuW. DaiQ.S. LuN. QiQ. LiZ.Y. YouQ.D. GuoQ.L. Apoptosis induction of oroxylin A in human cervical cancer HeLa cell line in vitro and in vivo.Toxicology20092571-2808510.1016/j.tox.2008.12.011 19135124
     [Google Scholar]
  28. KiralyG. SimonyiA.S. TuraniM. Micronucleus formation during chromatin condensation and under apoptotic conditions.Apoptosis201722220721910.1007/s10495‑016‑1316‑4
     [Google Scholar]
  29. Bossy-WetzelE. GreenD.R. Detection of apoptosis by annexin V labeling.Methods in enzymology; Elsevier2000151810.1016/S0076‑6879(00)22004‑1
     [Google Scholar]
  30. ElmoreS. Apoptosis: A review of programmed cell death.Toxicol. Pathol.200735449551610.1080/01926230701320337 17562483
     [Google Scholar]
  31. GuoY.J. PanW.W. LiuS.B. ShenZ.F. XuY. HuL.L. ERK/MAPK signalling pathway and tumorigenesis (Review).Exp. Ther. Med.20201931997200710.3892/etm.2020.8454 32104259
     [Google Scholar]
  32. LavoieH. GagnonJ. TherrienM. ERK signalling: A master regulator of cell behaviour, life and fate.Nat. Rev. Mol. Cell Biol.2020211060763210.1038/s41580‑020‑0255‑7 32576977
     [Google Scholar]
  33. BerraE. Diaz-MecoM.T. MoscatJ. The activation of p38 and apoptosis by the inhibition of Erk is antagonized by the phosphoinositide 3-kinase/Akt pathway.J. Biol. Chem.199827317107921079710.1074/jbc.273.17.10792 9553146
     [Google Scholar]
  34. BerraE. MunicioM.M. SanzL. FrutosS. Diaz-MecoM.T. MoscatJ. Positioning atypical protein kinase C isoforms in the UV-induced apoptotic signaling cascade.Mol. Cell. Biol.19971784346435410.1128/MCB.17.8.4346 9234692
     [Google Scholar]
  35. XiaZ. DickensM. RaingeaudJ. DavisR.J. GreenbergM.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.Science199527052401326133110.1126/science.270.5240.1326 7481820
     [Google Scholar]
  36. YangC. LuoJ. LuoX. JiaW. FangZ. YiS. LiL. Morusin exerts anti-cancer activity in renal cell carcinoma by disturbing MAPK signaling pathways.Ann. Transl. Med.20208632710.21037/atm.2020.02.107 32355771
     [Google Scholar]
  37. EidW. Abdel-RehimW. Neferine enhances the antitumor effect of mitomycin‐C in hela cells through the activation of p38‐MAPK pathway.J. Cell. Biochem.2017118103472347910.1002/jcb.26006 28328092
     [Google Scholar]
  38. YaoW. LinZ. WangG. LiS. ChenB. SuiY. HuangJ. LiuQ. ShiP. LinX. LiuQ. YaoH. Delicaflavone induces apoptosis via mitochondrial pathway accompanying G2/M cycle arrest and inhibition of MAPK signaling cascades in cervical cancer HeLa cells.Phytomedicine20196215297310.1016/j.phymed.2019.152973 31177019
     [Google Scholar]
  39. ThakuriaR. SarmaB.J.C. Drug-drug and drug-nutraceutical cocrystal/salt as alternative medicine for combination therapy: A crystal engineering approach.Crystals2018210110.3390/cryst8020101
     [Google Scholar]
  40. KumbharP. KolekarK. Co-crystal nanoarchitectonics as an emerging strategy in attenuating cancer: Fundamentals and applications.J. Control. Release20233531150117010.1016/j.jconrel.2022.12.042
     [Google Scholar]
  41. NascimentoA.L. FernandesR.P. Co-crystals of non-steroidal anti-inflammatory drugs (NSAIDs): Insight toward formation, methods, and drug enhancement.Particuology20215822724110.1016/j.partic.2021.03.015
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206364530241128044041
Loading
Discovery of a Novel Co-crystal of Chrysin and Oroxylin A with Anticancer Properties from Leaves of Oroxylum indicum
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) 25, 563 (2025); https://doi.org/10.2174/0118715206364530241128044041
/content/journals/acamc/10.2174/0118715206364530241128044041
/content/journals/acamc/10.2174/0118715206364530241128044041
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): apoptosis; caspase 3; chrysin; co-crystal; HeLa; MAPK; oroxylin A; Oroxylum indicum

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test